Silver Book Fact

From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states

Fact image

Grover F, Vemalapalli S, Carroll J, et al. 2016 Annual Report of The Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg. 2017; 103(3). http://www.sciencedirect.com/science/article/pii/S0003497516317659

Reference

Title
2016 Annual Report of The Society for Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry
Publication
Ann Thorac Surg
Publication Date
2017
Authors
Grover F, Vemalapalli S, Carroll J, et al
Volume & Issue
Volume 103, Issue 3
Pages
102-35
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…